Scholarlink

Background <p>Actionable driver mutations are currently found in less than half of the first diagnoses in non-small cell lung cancer (NSCLC). Identifying these mutations and deriving treatment recommendations require a&#xa0;comprehensive understanding of molecular genetics and interdisciplinary cooperation.</p> Objective <p>The aim of this review article is to clearly outline the current targeted systemic treatment options for metastatic NSCLC with driver mutations and to critically examine their effects and side effects.</p> Methods <p>A&#xa0;narrative review of studies relevant to regulatory approval and guideline-based recommendations is provided. The focus is on the molecular understanding of driver mutations and their response to drug treatment.</p> Results <p>Driver mutations in 9&#xa0;target structures presented are found with varying frequencies. The treatment landscape has evolved from targeted monotherapy to combination therapy consisting of a&#xa0;tyrosine kinase inhibitor and a&#xa0;bispecific antibody. When selecting targeted therapy options it is essential to have a&#xa0;thorough understanding of their efficacy and side effects and to tailor them to the patient’s needs.</p> Conclusion <p>The diagnostic aspects and treatment options for NSCLC have undergone impressive advances over the past 20&#xa0;years. In addition to conventional immunochemotherapy, specific inhibitors and antibodies are available in the era of personalized medicine following appropriate molecular testing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metastasiertes nichtkleinzelliges Lungenkarzinom mit Treiberalterationen

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Armin Frille

摘要

Background

Actionable driver mutations are currently found in less than half of the first diagnoses in non-small cell lung cancer (NSCLC). Identifying these mutations and deriving treatment recommendations require a comprehensive understanding of molecular genetics and interdisciplinary cooperation.

Objective

The aim of this review article is to clearly outline the current targeted systemic treatment options for metastatic NSCLC with driver mutations and to critically examine their effects and side effects.

Methods

A narrative review of studies relevant to regulatory approval and guideline-based recommendations is provided. The focus is on the molecular understanding of driver mutations and their response to drug treatment.

Results

Driver mutations in 9 target structures presented are found with varying frequencies. The treatment landscape has evolved from targeted monotherapy to combination therapy consisting of a tyrosine kinase inhibitor and a bispecific antibody. When selecting targeted therapy options it is essential to have a thorough understanding of their efficacy and side effects and to tailor them to the patient’s needs.

Conclusion

The diagnostic aspects and treatment options for NSCLC have undergone impressive advances over the past 20 years. In addition to conventional immunochemotherapy, specific inhibitors and antibodies are available in the era of personalized medicine following appropriate molecular testing.